MAPK9

Mitogen-activated protein kinase 9

171,854 patent compounds predicted against MAPK9, 116,056 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Vs-4718 (SCHEMBL47360)	1.00	9/20
SCHEMBL47302	0.84	9/20
SCHEMBL67602	0.52	6/20
SCHEMBL68940	0.64	5/20
SCHEMBL67984	0.72	4/20
SCHEMBL68793	0.68	4/20
SCHEMBL69095	0.67	4/20
SCHEMBL67820	0.67	4/20
SCHEMBL67376	0.64	4/20
SCHEMBL66923	0.60	4/20
SCHEMBL67192	0.60	4/20
SCHEMBL68165	0.59	4/20
SCHEMBL68343	0.55	4/20
SCHEMBL59547	0.55	4/20
SCHEMBL58735	0.54	4/20
SCHEMBL60289	0.53	4/20
SCHEMBL69401	0.53	4/20
SCHEMBL60366	0.51	4/20
SCHEMBL58416	0.50	4/20
SCHEMBL67023	0.73	3/20

Germline variants in MAPK9 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAPK9 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAPK9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer	PHASE3	RECRUITING
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.	PHASE3	UNKNOWN
Study of ASTX029 in Subjects With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE2	COMPLETED
Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK	PHASE1/PHASE2	RECRUITING
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors	PHASE1	COMPLETED
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies	PHASE1	RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPK9 binder may also engage these)

Protein	Name	Similarity
P49186	—	1.000	P49186 →
MAPK8	Mitogen-activated protein kinase 8	1.000	landscape →
Q9WTU6	—	0.999	Q9WTU6 →
P49187	—	0.998	P49187 →
Q8QHK8	—	0.995	Q8QHK8 →
P49185	—	0.995	P49185 →
Q90327	—	0.994	Q90327 →
MAPK10	Mitogen-activated protein kinase 10	0.991	landscape →
P79996	—	0.991	P79996 →
Q61831	—	0.991	Q61831 →
O42099	—	0.990	O42099 →
Q91Y86	—	0.989	Q91Y86 →
P62205	—	0.973	P62205 →
Q9DGD9	—	0.972	Q9DGD9 →
Q9U6D2	—	0.972	Q9U6D2 →
G1XJZ4	—	0.971	G1XJZ4 →
CHEK1	Serine/threonine-protein kinase Chk1	0.971	landscape →
B0XR80	—	0.970	B0XR80 →
Q4PC06	—	0.970	Q4PC06 →
Q4W6D3	—	0.970	Q4W6D3 →
Q0D0P5	—	0.970	Q0D0P5 →
Q4WSF6	—	0.970	Q4WSF6 →
Q52PH6	—	0.969	Q52PH6 →
Q0U4L8	—	0.969	Q0U4L8 →
O35280	—	0.969	O35280 →
Q09892	—	0.969	Q09892 →
Q1DUU8	—	0.969	Q1DUU8 →
Q8TGA9	—	0.969	Q8TGA9 →
Q56R42	—	0.969	Q56R42 →
A0A5B9GBF0	—	0.969	A0A5B9GBF0 →